Transforming Women's Health with Innovative Solutions

Learn more about OVA1plus


OVA1plusTM is a reflex process which first performs OVA1® and then performs OVERA® if the OVA1® result is in the intermediate range. OVA1® and OVERA® are FDA-cleared ovarian cancer risk assessment tests for women with pelvic masses.  These tests provide risk assessment for Ovarian Cancer risk prior to surgery and is better test for detection of Ovarian Cancer Risk than CA-125.

Performance Statistics:

• Negative Predictive Value of 98%
• Sensitivity of 96%*

Outperforms CA-125 especially in:

• Detecting Early-Stage Disease where is matters most
• Detecting risk in Pre-menopausal Women
• Sensitivity in African American Women

*OVA1 combined with clinical assessment & Imaging OVA1plus Results should be interpreted along with clinical and ultrasound assessment.

Explore Our Products

OVA1 Plus Logo


OVA1plus is a reflex process which performs OVA1 and OVERA, both FDA-cleared tests for women with adnexal masses. OVA1plus helps you further stratify your patient’s risk of malignancy for women with pelvic masses planned for surgery. Benefits of this enhanced test offering include; Reducing the falsely elevated rate by up to 50%, maintaining the high rate of detection (sensitivity) for ovarian cancer risk, continuing to provide confidence in low-risk results with a high negative predictive value, and increased specificity by up to 20%.

Aspira Genetix Logo


With a focus on women’s health, Aspira Labs® offers both comprehensive and targeted genetic testing options for Hereditary Breast and Ovarian cancer as well as Carrier Screening to help guide medical management for your patient.

ASPIRA Synergy Technology Transfer Logo

Synergy Technology Transfer

Aspira Synergy allows labs to significantly reduce the time needed to implement in-house testing solutions

Developed by a team of experts, Aspira Synergy informs medical choices for women’s health with the assistance of multi-marker proteins and state-of-the-art genetic testing for both carrier screening and hereditary cancer risk.